All The Claims

1. A muffling device, comprising:
an inner flow conditioner shaped as a generally conical frustum comprising an upstream base and a downstream base, a diameter of the upstream base being larger than a diameter of the downstream base, the inner flow conditioner comprising
an inlet approximate the upstream base,
a generally circular inner flow conditioner downstream end wall, the inner flow conditioner downstream end wall being generally orthogonal to a longitudinal axis of the conical frustum and comprising a plurality of generally longitudinally oriented inner flow conditioner downstream end wall holes, and
an inner flow conditioner sidewall shaped generally as a truncated cone, the inner flow conditioner sidewall tapering inwardly from approximate the upstream base to approximate the inner flow conditioner downstream wall, the inner flow conditioner sidewall comprising a plurality of generally laterally oriented inner flow conditioner sidewall holes; and

an exhaust can disposed substantially around the inner flow conditioner and shaped as a generally circular cylinder, the exhaust can comprising
a generally annular upstream end wall disposed approximate the upstream base of the inner flow conditioner and substantially circumscribing the upstream base of the inner flow conditioner,
a generally circular exhaust screen comprising a plurality of exhaust screen holes, and
a generally circular exhaust can sidewall extending from approximate the upstream end wall to approximate the exhaust screen;

wherein the inner flow conditioner and the exhaust can are configured to conduct a fluid inward through the inlet into the inner flow conditioner, through the inner flow conditioner downstream end wall discharge openings and the inner flow conditioner sidewall discharge openings into the exhaust can, and outward through the exhaust screen discharge openings.
2. The muffling device of claim 1, wherein the exhaust screen is outwardly curved.
3. The muffling device of claim 1, further comprising a bleed flow conduit operatively connected between the inlet opening of the inner flow conditioner and a bleed air valve configured to selectively bleed a compressor of a gas turbine engine via the bleed flow conduit.
4. The muffling device of claim 1, wherein a length of the exhaust can is less than about one third of the sum of the length of the exhaust can and a length of the bleed flow conduit.
5. The muffling device of claim 1, wherein the exhaust can interior is substantially devoid of flow obstructions between the plurality of inner flow conditioner holes and the exhaust screen holes.
6. The muffling device of claim 1, wherein a ratio of an effective flow area of the inner flow conditioner downstream end wall holes and the inner flow conditioner sidewall hoes to an effective flow area of the inlet is about 0.7 to about 1.75.
7. The muffling device of claim 1, wherein the ratio of the effective flow area of the inner flow conditioner downstream end wall holes and the inner flow conditioner sidewall hoes to the effective flow area of the inlet is about 0.75 to about 0.86.
8. The muffling device of claim 1, wherein a ratio of an effective flow area of the exhaust screen holes to an effective flow area of the inlet is about 0.9 to about 2.8.
9. The muffling device of claim 1, wherein the ratio of the effective flow area of the exhaust screen holes to the effective flow area of the inlet is about 1.0 to about 1.9.
10. The muffling device of claim 1, wherein the ratio of the effective flow area of the exhaust screen holes to the effective flow area of the inlet is about 2.6 to about 2.7.
11. The muffling device of claim 1, wherein a ratio of an interior volume of the inner flow conditioner to an interior volume of the exhaust can is about 0.06 to about 0.40.
12. The muffling device of claim 1, wherein a ratio of an interior volume of the inner flow conditioner to an interior volume of the exhaust can is about 0.10 to about 0.22.
13. The muffling device of claim 1, wherein a ratio of an interior volume of the inner flow conditioner to an interior volume of the exhaust can is about 0.125 to about 0.195.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is internalized within the carcinoma cells to which it binds.
2. An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is cytotoxic to the carcinoma cells to which it binds.
3. An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is cytostatic to the carcinoma cells to which it binds.
4. An antibody which specifically binds PSCA on the cell surface of carcinoma cells, and is internalized and kills the carcinoma cells to which it reacts.
5. An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is internalized and is cytostatic to the carcinoma cells to which it binds.
6. An antibody, comprising an antigen binding site, wherein the antigen binding site recognizes and binds the N terminal region of PSCA.
7. An antibody, comprising an antigen binding site, wherein the antigen binding site recognizes and binds the C terminal region of PSCA.
8. An antibody, comprising an antigen binding site, wherein the antigen binding site recognizes and binds the middle region of PSCA.
9. The antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 which is a monoclonal antibody.
10. A monoclonal anti-idiotypic antibody reactive with an idiotype on the antibody of of claim 1, 2, 3, 4, 5, 6, 7, or 8.
11. A recombinant protein which is a murinehuman chimeric antibody having (a) a variable region of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 and (b) a constant region of human origin.
12. A polypeptide that binds PSCA comprising the antigen-binding region of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8.
13. A monoclonal antibody, the antigen-binding region of which competitively inhibits the immunospecific binding of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 to its target antigen.
14. A bispecific antibody with a binding specificity for two different antigens, one of the antigens being that with which the antibody of claim 1, 2, 3, 4, 5, 6, 7, or 8 binds.
15. An Fab, F(ab)2 or Fv fragment of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8.
16. A single chain antibody molecule that binds PSCA comprising an antigen binding region of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8.
17. An immunoconjugate comprising the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 joined to a therapeutic agent.
18. An immunoconjugate comprising the recombinant protein of claim 11 joined to a therapeutic agent.
19. An inununoconjugate comprising the polypeptide of claim 12 joined to a therapeutic agent.
20. An immunoconjugate comprising the monoclonal antibody of claim 9 joined to a therapeutic agent.
21. An immunoconjugate comprising the bispecific antibody of claim 14 joined to a therapeutic agent.
22. An immunoconjugate comprising the single chain antibody molecule of claim 16 joined to a therapeutic agent.
23. The immunoconjugate of any one of claims 17-22, wherein the therapeutic agent is a cytotoxic agent.
24. The immunoconjugate of claim 23, wherein the cytotoxic agent is selected from a group consisting of ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethiduim bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, maytansinoids, and glucocorticoidricin.
25. A pharmaceutical composition useful in killing human cells expressing the PSCA antigen on the cell surface, comprising a pharmaceutically effective amount of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 and a pharmaceutically acceptable carrier.
26. A pharmaceutical composition useful in killing human cells expressing the PSCA antigen on the cell surface, comprising a pharmaceutically effective amount of the immunoconjugate of any one of the claims 17-22, and a pharmaceutically acceptable carrier.
27. A method for treating a subject suffering from a malignant disease characterized by cells having the PSCA antigen on the cell surface which comprises administering to the subject an effective amount of an immunoconjugate of any one of the claims 17-22 such that the immunoconjugate binds the PSCA antigen and kills said cells thereby treating the subject.
28. A method for selectively killing tumor cells expressing PSCA comprising contacting said tumor cells with an amount of the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 for a time sufficient to kill said cells.
29. A method for prolonging the life of a subject with a cancer associated with PSCA, comprising administering to the subject a monoclonal antibody which binds to PSCA in an amount effective so as to inhibit the cancer, thereby prolonging the life of the subject.
30. The method of claim 29, wherein said antibody is conjugated to a cytotoxic agent.
31. The method of claim 30, wherein said cytotoxic agent is selected from the group consisting of ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethiduim bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, maytansinoids, and glucocorticoidricin.
32. The method of claim 30, wherein said cytotoxic agent is a radioactive isotope.
33. The method of claim 32, wherein said radioactive isotope is selected from the group consisting of 212Bi, 131I, 131In, 90Y and 186Re.
34. The method of claim 29, wherein said monoclonal antibody is not conjugated to a cytotoxic agent.
35. The method of claim 29, wherein the monoclonal antibody comprises murine antigen binding region residues and human antibody residues.
36. The method of claim 29, wherein the monoclonal antibody is a humanized antibody.
37. The method of claim 29, wherein the monoclonal antibody is a human antibody.
38. The method of claim 29, wherein the cancer is prostate cancer.
39. The method of claim 29, wherein the cancer is metastatic prostate cancer.
40. The method of claim 29, wherein the cancer is bladder cancer.
41. The method of claim 29, wherein the cancer is a metastatic bladder cancer.
42. The method of claim 29, wherein the cancer is a pancreatic cancer.
43. The method of claim 42, wherein the cancer is a metastatic pancreatic cancer.
44. The method of claim 29, further comprising administering to the patient a chemotherapeutic drug.
45. The method of claim 29, further comprising administering to the patient hormone ablation therapy.
46. The method of claim 29, further comprising administering to the patient hormone antagonist therapy.
47. The method of claim 29, further comprising administering radiation therapy to the patient.
48. A method of inhibiting the growth of cancer cells expressing PSCA, comprising administering to a patient a combination of monoclonal antibodies which bind to PSCA in an amount effective so as to inhibit growth of the cancer cells.
49. The method of claim 48, wherein the combination of monoclonal antibodies comprise monoclonal antibodies of at least two different isotypes.
50. The method of claim 48, wherein the combination of monoclonal antibodies comprise monoclonal antibodies with different epitope specificities.
51. The method of claim 48, wherein the combination of monoclonal antibodies comprises monoclonal antibodies 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 and 4A10 produced by the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12618, HB-12615, and HB-12617, respectively, as deposited with the American Type Culture Collection.
52. The method of claim 46, wherein the combination of monoclonal antibodies is selected from the group consisting of mAb 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 and 4A10 produced by the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12618, HB-12615, and HB-12617, respectively, as deposited with the American Type Culture Collection.

1. A heating system for heating a living being, the heating system comprising:
an infrared laser system for illuminating the living being with infrared laser light, thereby heating the living being, wherein the illuminating the living being with the infrared laser light can be confined to a location of the living by a collimation of the infrared laser light.
2. The heating system of claim 1, wherein the infrared laser system comprises one or several vertical-cavity surface-emitting lasers.
3. The heating system of claim 1, wherein the heating system further comprises:
a presence signal providing unit for providing a presence signal being indicative of whether a living being is present such that the living being is illuminatable by the infrared light from the infrared laser system; and
a control unit for controlling the infrared laser system wherein the controlling depends on the presence signal.
4. The heating system of claim 3, wherein the presence signal is further indicative of the location of the living being to be heated, wherein the control unit is adapted to:
determine the location of the living being depending on the provided presence signal, and
control the infrared laser system to provide the infrared laser light at the location of the living being.
5. The heating system of claim 3, wherein the presence signal is an image of the living being wherein the control unit is adapted to:
detect predefined regions on the living being from the provided image, and
control the infrared laser system to provide the infrared laser light to the predefined regions.
6. The heating system of claim 3, wherein the presence signal providing unit is an image of the living being wherein the control unit is adapted to:
associate a first temperature with a temperature of a living being, and
control the infrared laser system depending on a determined temperature value in the image that equals the first temperature.
7. The heating system of claim 1, wherein the heating system is adapted to be used for heating a person in a vehicle.
8. The heating system of claim 7, wherein the vehicle comprises a window and wherein the infrared laser system is adapted to also heat the window.
9. The heating system of claim 7, wherein the living being is a driver of the vehicle, wherein the heating system comprises an attention signal providing unit for providing an attention signal, if the driver’s attention is to be attracted, and a control unit for controlling the infrared laser system depending on the provided attention signal.
10. A camera system for cooperating with the heating system of claim 1, wherein the heating system comprises a control unit for controlling the infrared laser system depending on a presence signal, wherein the camera system is adapted to acquire an image of the living being and to send the acquired image as the presence signal to the heating system for allowing the control unit of the heating system to control the infrared laser system of the heating system depending on the acquired image.
11. A driver assist system for cooperating with the heating system of claim 9, wherein the driver assist system is adapted to
detect a dangerous situation,
generate an attention signal, if a dangerous situation has been detected, and
send the attention signal to the heating system, in order to allow the control unit of the heating system to control the infrared laser system of the heating system depending on the presence of the attention signal.
12. A vehicle comprising the heating system as claim 1.
13. The vehicle of claim 12, wherein the heating system comprises several infrared lasers distributed within the vehicle.
14. A heating method for heating a living being, the heating method comprising illuminating the living being with infrared laser light by an infrared laser system wherein the illuminating the living being is confined to a location of the living being by collimation of the infrared laser light.
15. A heating computer program for heating a living being, the heating computer program comprising program code means for causing the heating system of claim 1 to carry out the heating method comprising illuminating the living being with infrared laser light by an infrared laser system, wherein the illuminating the living being is confined to a location of the living being by collimation of the infrared laser light, wherein the computer program is run on a computer controlling the heating system.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An anti-adhesion sheet having an interior region and an edge region encompassing the interior region, and comprising at least one radiopaque marker, wherein the radiopaque marker defines the edge region of the sheet.
2. The sheet of claim 1 wherein the sheet has a plurality of corners, and wherein the edge region includes a radiopaque marker located in each respective corner of the sheet.
3. The sheet of claim 1 wherein the radiopaque marker extends continuously along the edge region of the sheet.
4. An anti-adhesion sheet having an interior region and an edge region encompassing the interior region, and comprising at least one radiopaque marker located at least partially in an interior region of the sheet.
5. The sheet of claim 4 wherein the marker is located along a midline of the sheet.
6. The sheet of claim 4 wherein the marker is located continuously along a midline of the sheet.
7. A tab-less anti-adhesion sheet having a radiopaque marker.
8. An anti-adhesion sheet having a bulk region and a tab region, wherein the bulk region comprises a radiopaque marker.
9. An anti-adhesion sheet having a first face and a second face producing a first thickness therebetween, wherein the first face has a recess therein to produce a bend zone having a second wall thickness, wherein the first wall thickness is greater than the second wall thickness.
10. An anti-adhesion sheet having a stiffness enhancement feature selected from the group consisting of a compression ridge and a rib.
11. A method comprising:
a) providing a vertebral body having an anterior wall defining a first radius of curvature,
b) providing an anti-adhesion sheet having a concave face defining a second radius of curvature, wherein the first radius of curvature is greater than the second radius of curvature, and
c) attaching the concave face of the anti-adhesion sheet to the anterior wall of the vertebral body.
12. An anti-adhesion sheet comprising a dye.
13. The sheet of claim 12 wherein the sheet is translucent.
14. The sheet of claim 12 wherein the sheet is transparent.
15. An anti-adhesion sheet having bony purchase features selected from the group consisting of mesh, adhesive and pre-attached bone anchors.
16. The anti-adhesion sheet of claim 15 wherein the bony purchase feature is a mesh.
17. The anti-adhesion sheet of claim 15 wherein the bony purchase feature is an adhesive.
18. The anti-adhesion sheet of claim 15 wherein the bony purchase feature is a pre-attached bone anchor.
19. The anti-adhesion sheet of claim 18 wherein the pre-attached bone anchor is in-line attached.
20. The anti-adhesion sheet of claim 18 wherein the pre-attached bone anchor is included angle.